首站-论文投稿智能助手
典型文献
Anticancer activity of ?9-tetrahydrocannabinol and cannabinol in vitro and in human lung cancer xenograft
文献摘要:
Objective: To investigate the effects of ?9-tetrahydrocannabinol, the principal psychoactive compound of Cannabis sativa, and cannabinol, a ?9-tetrahydrocannabinol degradative product, on human non-small cell lung cancer cells.Methods: ?9-Tetrahydrocannabinol and cannabinol were tested for anticancer activity in human non-small cell lung cancer (A549) cells. The effects on cell proliferation, apoptosis, and phosphorylation profiles were examined. The effects of ?9-tetrahydrocannabinol and cannabinol on tumor growth were also investigated using a xenograft nude mouse model. Apoptosis and targeted phosphorylation were verified by immunohistochemistry. Results: ?9-Tetrahydrocannabinol and cannabinol significantly inhibited cell proliferation and increased the number of apoptotic cells in a concentration-dependent manner. The ?9-tetrahydrocannabinol- and cannabinol-treated cells had lower levels of phosphorylated protein kinase B [AKT (S473)], glycogen synthase kinase 3 alpha/beta, and endothelial nitric oxide synthase compared to the controls. The study of xenograft mice revealed that tumors treated with 15 mg/kg ?9-tetrahydrocannabinol or 40 mg/kg cannabinol were significantly smaller than those of the control mice. The tumor progression rates in mice treated with 15 mg/kg ?9-tetrahydrocannabinol or 40 mg/kg cannabinol were significantly slower than in the control group. Conclusions: These findings indicate that ?9-tetrahydrocannabinol and cannabinol inhibit lung cancer cell growth by inhibiting AKT and its signaling pathways, which include glycogen synthase kinase 3 alpha/beta and endothelial nitric oxide synthase.
文献关键词:
作者姓名:
Surang Leelawat;Kawin Leelawat;Thaniya Wannakup;Worawan Saingam;Nanthaphong Khamthong;Fameera Madaka;Athip Maha;Patamaporn Pathompak;Lukman Sueree;Thanapat Songsak
作者机构:
Medicinal Cannabis Research Institute,College of Pharmacy,Rangsit University,Pathum Thani 12000,Thailand;Department of Surgery,Bumrungrad International Hospital,Bangkok 10110,Thailand;Drug and Herbal Product Research and Development Center,College of Pharmacy,Rangsit University,Pathum Thani 12000,Thailand;College of Oriental Medicine,Rangsit University,Pathum Thani 12000,Thailand;Department of Pharmacognosy,College of Pharmacy,Rangsit University,Pathum Thani 12000,Thailand
引用格式:
[1]Surang Leelawat;Kawin Leelawat;Thaniya Wannakup;Worawan Saingam;Nanthaphong Khamthong;Fameera Madaka;Athip Maha;Patamaporn Pathompak;Lukman Sueree;Thanapat Songsak-.Anticancer activity of ?9-tetrahydrocannabinol and cannabinol in vitro and in human lung cancer xenograft)[J].亚太热带生物医学杂志(英文版),2022(08):323-332
A类:
cannabinol,Tetrahydrocannabinol
B类:
Anticancer,activity,tetrahydrocannabinol,vitro,human,lung,xenograft,Objective,To,effects,principal,psychoactive,compound,Cannabis,sativa,degradative,product,cells,Methods,were,tested,anticancer,A549,proliferation,apoptosis,phosphorylation,profiles,examined,growth,also,investigated,using,nude,mouse,model,Apoptosis,targeted,verified,by,immunohistochemistry,Results,significantly,inhibited,increased,number,apoptotic,concentration,dependent,manner,treated,had,levels,phosphorylated,protein,kinase,AKT,S473,glycogen,synthase,alpha,beta,endothelial,nitric,oxide,compared,controls,study,mice,revealed,that,tumors,smaller,than,those,progression,rates,slower,group,Conclusions,These,findings,indicate,inhibiting,its,signaling,pathways,which,include
AB值:
0.443987
相似文献
SNORA23 inhibits HCC tumorigenesis by impairing the 2?-O-ribose methylation level of 28S rRNA
Zhiyong Liu;Yanan Pang;Yin Jia;Qin Qin;Rui Wang;Wei Li;Jie Jing;Haidong Liu;Shanrong Liu-Department of Laboratory Diagnostics,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Department of Gastroenterology and Hepatology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Gastroenterology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Institute of Pancreatic Diseases,Shanghai 200433,China;Department of Chemistry and State Key Laboratory of Molecular Engineering of Polymers,Fudan University,Shanghai 200433 China;Department of General Surgery,Changzheng Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China
Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
Xinyi Zhou;Qian Xiao;Dongliang Fu;Haochen Zhang;Yang Tang;Jinjie He;Yeting Hu;Xiangxing Kong;Fei Teng;Xiangrui Liu;Ying Yuan;Kefeng Ding-Department of Colorectal Surgery and Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Medical Oncology,Key Laboratory of Cancer Prevention and Intervention,Ministry of Education,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Hangzhou Oncocare Co Ltd,Hangzhou 310009,China;Department of Pharmacology,Zhejiang University School of Medicine,Hangzhou 310058,China;Cancer Center,Zhejiang University,Hangzhou 310009,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer
Xu Zhang;Na Qin;Jingyi Fan;Chang Zhang;Qi Sun;Yayun Gu;Meng Zhu;Erbao Zhang;Juncheng Dai;Guangfu Jin;Hongxia Ma;Zhibin Hu;Hongbing Shen-Department of Epidemiology,Center for Global Health,School of Public Health,Nanjing Medical University,Nanjing 211166,China;Jiangsu Key Lab of Cancer Biomarkers,Prevention and Treatment,Collaborative Innovation Center for Cancer Personalized Medicine,Nanjing Medical University,Nanjing 211166,China;Health Management Center,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou Municipal Hospital,Gusu School,Nanjing Medical University,Suzhou 215008,China;Research Units of Cohort Study on Cardiovascular Diseases and Cancers,Chinese Academy of Medical Sciences,Beijing 100730,China
Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells
Hong Yu;Hong-ying Gao;Hua Guo;Gui-zhen Wang;Yi-qing Yang;Qian Hu;Li-jun Liang;Qun Zhao;Da-wei Xie;Yu Rao;Guang-biao Zhou-School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 100029,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;MOE Key Laboratory of Protein Sciences,School of Pharmaceutical Sciences,MOE Key Laboratory of Bioorganic Phosphorus Chemistry&Chemical Biology,and School of Medicine and Collaborative Innovation Center of Biotherapy,Tsinghua University,Beijing 100084,China;Hubei University of Medicine,Shiyan 442000,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。